Business Strategies Adopted By Major Players In The Companion Diagnostics Market
                     MarketsandMarkets 
Presents
Companion Diagnostics Market worth $9.9 billion by 2026
https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-15557
1681.html
The report "Companion Diagnostics Market by Product (Assays, Kits, Software & Services), 
Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology 
Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026", the global 
companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion 
in 2021, at a CAGR of 12.6%.
Browse 322 market data Tables and 51 Figures spread through 331 Pages and in-depth TOC on 
"Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, 
NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User 
(Pharma Companies, CROs), Region - Global Forecast to 2026"
The policy programs to provide effective care to patients with cancer, high drug development 
activity, structured regulatory framework in the region, and large patient pool undergoing 
advanced medical testing. Emerging economies such as China, Japan, and India are providing 
lucrative opportunities for the players operating in the companion diagnostics market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681
Objectives of the Study:
• The assays, kits & reagents segment accounted for the largest share
The companion diagnostics market is segmented into assays, kits & reagents, and software 
& services. The assays, kits & reagents accounted for the largest share of the companion 
diagnostics market in 2020, mainly due to the availability of a wide range of products and 
increasing use of assays and kits in different therapeutic areas.
• PCR segment to register the highest growth rate
The companion diagnostics market is segmented into polymerase chain reaction 
(PCR), next-generation sequencing (NGS), in situ hybridization (ISH), 
immunohistochemistry (IHC), and other technologies. In 2020, the PCR segment 
accounted for the largest share of the companion diagnostics market. Factors such 
as the ease of use and widespread availability of PCR kits & reagents in companion 
diagnostic testing, and growing applications of PCR in the high-throughput 
detection of mutants with a limited or low allele frequency of genes.
• Cancer segment to register the highest growth rate
• The pharmaceutical & biotechnology companies segment accounted for the largest share
• North America is the largest regional
Speak to Analyst: https://www.marketsandmarkets.com/
This report categorizes the companion diagnostics market into the following segments and 
subsegments:
By Product & Service
• Assays, Kits & Reagents
• Software & Services
By Technology
• Polymerase Chain Reaction
• Next-generation Sequencing
• In Situ Hybridization
• Immunohistochemistry
• Other Technologies
By Indication
• Cancer `
• Neurological Disorders
• Cardiovascular Diseases
• Infectious Diseases
• Other Indications
By End User
• Pharmaceutical & Biopharmaceutical Companies
• Reference Laboratories
• Contract Research Organizations
• Other End Users
The major players operating in this market are F. Hoffmann-La Roche Ltd., Agilent 
Technologies, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Abbott Laboratories, Inc., 
Almac Group, Danaher Corporation, Illumina Inc., bioMérieux SA, Myriad Genetics, Inc., 
Sysmex Corporation, Abnova Corporation, Guardant Health, Inc., ICON Plc, BioGenex 
Laboratories, Inc., Invivoscribe Technologies, ArcherDX, Inc., NG Biotech, Q² Solutions, 
Amoy Diagnostics Co., Ltd., Abacus Diagnostica Oy, Asuragen Inc., SAGA Diagnostics, 
Meso Scale Diagnostics, LLC., and Creative Biolabs and Among Others
Companies Insight
In 2020, F. Hoffmann-La Roche Ltd. held the leading position in the companion diagnostics 
market. The company’s leading position in this market can be attributed to its strong global sales 
and distribution network, enabling it to market its products in various countries effectively. In 
addition, F. Hoffmann-La Roche Ltd. invests a significant amount of its revenue on R&D. This 
enables the company to develop and launch new products in the market. Roche adopts 
inorganic growth strategies to increase its dominance in this market. For instance, in September 
2021, the company acquired TIB Molbiol Group (Germany). This acquisition strengthened its 
broad portfolio of molecular diagnostics solutions with the addition of a wide range of assays for 
infectious diseases, such as the identification of SARS-CoV-2 variants.
In 2020, Agilent Technologies, Inc. accounted for the second-largest share of the companion 
diagnostics market. The company’s leading position in this market can be attributed to its strong 
sales and distribution network globally, enabling it to market its products in various countries 
effectively. Agilent Technologies invests a significant amount of its revenue in R&D, enabling it to 
develop and launch new products in the market. In October 2021, the company announced that 
its PD-L1 IHC 22C3 pharmDx assay was labeled for use in TNBC in the European Union.
Contact Us
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
Press release: 
https://www.marketsandmarkets.com/PressReleases/companion-diagnostics.asp
Research Insights: 
https://www.marketsandmarkets.com/ResearchInsight/companion-diagnostics-market.asp
About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche 
opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently 
servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. 
Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for 
their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets 
following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with 
the clients to identify new opportunities, identify most important customers, write "Attack, avoid 
and defend" strategies, identify sources of incremental revenues for both the company and its 
competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top 
players across leaders, emerging companies, innovators, strategic players) annually in high growth 
emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies 
this year for their revenue planning and help them take their innovations/disruptions early to the 
market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" 
connects over 200,000 markets and entire value chains for deeper understanding of the unmet 
insights along with market sizing and forecasts of niche markets.